Shanghai Fosun Pharmaceutical Group Co Ltd (2196:HK) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Shanghai Fosun Pharmaceutical Group Co Ltd stock forecast from 0 analysts, the average analyst target price for Shanghai Fosun Pharmaceutical Group Co Ltd is not available over the next 12 months. Shanghai Fosun Pharmaceutical Group Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Shanghai Fosun Pharmaceutical Group Co Ltd is Bearish, which is based on 3 positive signals and 10 negative signals. At the last closing, Shanghai Fosun Pharmaceutical Group Co Ltd’s stock price was HKD 11.76. Shanghai Fosun Pharmaceutical Group Co Ltd’s stock price has changed by +3.34% over the past week, -13.53% over the past month and -49.53% over the last year.
No recent analyst target price found for Shanghai Fosun Pharmaceutical Group Co Ltd
No recent average analyst rating found for Shanghai Fosun Pharmaceutical Group Co Ltd
Company Overview Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API's and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China. Read Less
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical D...Read More
Frequently Asked Questions About Shanghai Fosun Pharmaceutical Group Co Ltd (2196:HK) Stock
Stock Target Advisor's fundamental analysis for Shanghai Fosun Pharmaceutical Group Co Ltd's stock is Bearish.
2196:HK stock's dividend yield is 3.59%.
Our analysis grades 2196:HK stock's dividend yield at F. This means that 2196:HK stock's dividend yield is above 45% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 2196:HK may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 2196:HK's stock to indicate what its average analyst target is.
2196:HK stock's Price/Earning ratio is 13.20.
Our analysis grades 2196:HK stock's Price / Earning ratio at F. This means that 2196:HK stock's Price/Earning ratio is above 60% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 2196:HK may be a overvalued for its sector.
The last closing price of 2196:HK's stock was HKD 11.76.
The most recent market capitalization for 2196:HK is HKD 59.78B.
Unfortunately we do not have enough analyst data on 2196:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Shanghai Fosun Pharmaceutical Group Co Ltd's stock.
As per our most recent records Shanghai Fosun Pharmaceutical Group Co Ltd has 0 Employees.
Shanghai Fosun Pharmaceutical Group Co Ltd's registered address is Building A, Shanghai, China, 200233.
You can get more information about it from Shanghai Fosun Pharmaceutical Group Co Ltd's website at https://www.fosunpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 2196:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
